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Summary
Brain death (BD), a non-immunological factor of renal injury, triggers an
inflammatory process causing pathological signs of cell death in the kidney,
such as necrosis and apoptosis. Kidneys from brain dead donors show lower
success rates than kidneys from living donors and one strategy to improve
transplantation outcome is to precondition the donors. For the first time,
anti-rat thymoglobulin (rATG) was administered in an experimental brain
death animal model to evaluate if it could ameliorate histopathological
damage and improve organ function. Animals were divided into three groups:
V (n = 5) ventilated for 2 h; BD (n = 5) brain death and ventilated for 2 h; and
BD+rATG (n = 5) brain death, ventilated for 2 h, rATG was administered
during brain death (10 mg/kg). We observed lower creatinine levels in treat-
ment groups (means): V, 0·88 6 0·22 mg/dl; BD, 1·37 6 0·07 mg/dl; and
BD+rATG, 0·64 6 0·02 mg/dl (BD versus BD+rATG, P < 0·001). In the BD
group there appeared to be a marked increase of ATN, whereas ATN was
decreased significantly in the rATG group (V, 2·25 6 0·5 versus BD,
4·75 6 0·5, P < 0·01; BD+rATG, 2·75 6 0·5 versus BD 4·75 6 0·5 P < 0·01).
Gene expression was evaluated with reverse transcription–polymerase chain
reaction; tumour necrosis factor (TNF)-a, interleukin (IL)-6, C3, CD86
showed no significant difference between groups. Increased IL-10 and
decreased CCL2 in BD+rATG compared to BD (both cases P < 0·01). Myelop-
eroxidase was increased significantly after the brain death setting (V: 32 6 7·5
versus BD: 129 6 18). Findings suggest that rATG administered to potential
donors may ameliorate renal damage caused by BD. These findings could
contribute in the search for specific cytoprotective interventions to improve
the quality and viability of transplanted organs.
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Introduction
Critical care teams work to avoid or minimize injury before
brain death. However, once brain death is diagnosed and the
patient or their family express their wish to donate organs,
efforts are directed to improve organ quality and the subse-
quent transplant outcome [1]. Brain dead donors represent
the most important source of kidneys for transplant [2], but
transplanted kidneys from these donors suffer from lower
success rates than grafts from living donors [3]. These poor
results may be attributed to the pathophysiological changes
that take place during brain death [3]. Different approaches
have been used to improve transplant outcomes, includ-
ing treating the recipient, intervening with a preservation
solution or preconditioning the donor [2]. In an elegant
review of donor intervention and organ preservation, Feng
[4] explained that donor management has the best potential
to improve the quality and size of the organ supply.
Brain death causes an increase in parasympathetic tone
and, subsequently, intense sympathetic stimulation with
endogenous catecholamine release. This process results in
vasoconstriction, secondary tissue ischaemia, changes in
adenosine triphosphate (ATP production) and the produc-
tion of oxygen-free radicals. Additionally, the production of
cytosolic calcium increases and nitric oxide synthase concen-
tration is augmented. The subsequent hypotensive stage,
which is characterized by diminished sympathetic activity,
may reduce oxygen availability to the tissues [5]. Brain death
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is also associated with higher cytokine levels and systemic
proinflammatory changes [6]. Immunological responses
activate endothelial cells and proinflammatory genes [7],
and the inflammatory process generates pathological signs of
cell death such as kidney necrosis and apoptosis. Moreover,
activation of adhesion molecules and inflammatory media-
tors leads to a non-specific immune response in the kidney
that may cause acute rejection in the immediate post-
transplantation period [8].
Acute tubular necrosis (ATN) in kidneys from brain dead
donors is generally treated with interventions directed at
recipients. However, this approach requires an important
immunosuppressive load, and consequent higher costs for
the health-care system are probable. As brain death has a
specific cytokine profile, brain dead donors require a unique
approach to preserve their organs [9]. Donors pretreated
with steroids show decreased proinflammatory cytokine
expression in tissues and serum [10]. In an animal model,
Pratschke et al. [7] observed that preconditioning brain dead
donors with steroids reduces ischaemia/reperfusion injury
rate in kidney recipients.
Anti-thymocyte immunoglobulin (Ig) (ATG) (Thymoglo-
bulin®; Genzyme, Cambridge, MA, USA) is a purified frac-
tion of IgG from the sera of rabbits immunized against
human thymocytes and is administered commonly to recipi-
ents in renal transplant settings. In a previous in-vitro study,
ATG antibodies affected the binding and/or expression of
ligands such as intercellular adhesion molecule 1 (ICAM-1)
and surface molecules such as lymphocyte function-
associated antigen 1 (LFA1), which intervene in the
leucocyte–endothelium interaction. ATG also contains anti-
CCR7, anti-CXCR4 and anti-CCR5 antibodies that inhibit
leucocyte homing and trafficking to the graft by means of
binding to chemokine receptors [11].
No strategy directed at brain dead potential donors has
been demonstrated to be sufficiently reliable and consistent.
To the best of our knowledge, this is the first experimental
study in which ATG was administered to brain dead poten-
tial donors. We explored whether administering ATG to the
donor organ-to-be diminished histological damage and
improved renal function in the organ to be transplanted. Of
note, thymoglobulin was not associated with immunosup-
pressants or other drugs, as is generally the case in clinical
contexts to evaluate thymoglobulin without the complicat-
ing effects of other drugs.
Materials and methods
Animals
Fifteen Sprague–Dawley male rats (300 6 30 g; Veterinary
Faculty, University of Buenos Aires, Argentina) were submit-
ted to controlled macro- and microenvironmental condi-
tions, with access to water and standard laboratory chow ad
libitum. All experiments were performed in accordance with
the guidelines set by the National Institutes of Health (NIH
publication no. 28, revised 1996).
Generation and characterization of rATG
The rabbit anti-rat thymocyte immunoglobulin (rATG) was
provided by Genzyme and produced analogously to com-
mercial ATG (Thymoglobulin®). Rabbits were immunized
with a mixture of thymocytes of four strains of rats
(Sprague–Dawley, F344 Fisher, Lewis and Long Evans). Thy-
mocyte suspensions were prepared with thymi from various
donor rats. Fifty New Zealand White rabbits were immu-
nized twice, 2 weeks apart, and terminally bled 2 weeks after
the last immunization. Total rabbit IgG obtained from the
serum was pooled and purified with a process similar to
Thymoglobulin® (Genzyme). Control rabbit IgG was puri-
fied similarly from whole normal rabbit serum.
Experimental design
Rats were divided randomly into three groups: group V
(n = 5) animals without brain death that were ventilated
mechanically for 2 h; group BD (n = 5) animals with brain
death that were ventilated mechanically for 2 h; and group
BD and rATG (n = 5) animals with brain death that were
ventilated mechanically for 2 h. Immediately after the brain
death diagnosis, rATG was administered intravenously
(10 mg/kg; Genzyme). The dose was suggested by the
manufacturer.
All rats were anaesthetized with a combination of ket-
amine (80 mg/kg; Hollyday, Buenos Aires, Argentina) and
midazolam (5 mg/kg; Richmond, Buenos Aires, Argentina)
administered intraperitoneally, and lidocaine was used as a
local anaesthetic. Animals were placed in a sternal recum-
bent position and a 0·5-cm-long front lateral trepanation
was performed to insert a Fogarty no. 3 balloon catheter.
Animals were placed in the dorsal decubitus position to place
a no. 22 cannula in the right carotid artery and another no.
22 cannula in the left jugular vein. The artery pathway
was connected to a multi-parametric DYNE MCO-300-07
monitor to control blood pressure. The venous pathway was
connected to an infusion pump to administer physiological
solution (5 ml/kg/h). Animals were ventilated with a Neo
Net ventilator (Tecme SA, Cordoba, Argentina) (VT, 3 ml;
TI, 0·25; I : E, 1:2·0; FR, 80; Peep, 5; FIO, 40%). The balloon
was then inflated at a speed of 50 ml/min to reach 600–800 ml
and produce brain death. Brain death was diagnosed by
the absence of a corneal reflex and a positive apnoea test.
Animals were ventilated for 2 h, and blood pressure was
kept constant at 60–120 mmHg (Fig. 1). Noradrenaline was
administered (20 mg/ml; Biol, Buenos Aires, Argentina)
to stabilize hypotensive (<60 mmHg) animals within the
desired blood pressure range. After 2 h of brain death [12], a
blood sample was collected, the animals were killed and a left
kidney sample was collected for histopathological analysis.
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Blood analysis
Blood samples were used to determine urea and creatinine
levels, as quantified by kinetic ultraviolet and kinetic colori-
metric assays, respectively (Mindray 300).
Renal histopathology
Pathological samples were analysed by a pathologist blind to
the group assignments. The kidneys were fixed in a 10%
neutral buffered formalin solution, embedded in paraffin
and used for histopathological examination. Sections (4 mm
thick) were cut, deparaffinized, hydrated and stained with
haematoxylin and eosin. The renal sections were examined
for cortical tubular epithelial necrosis in a blind fashion.
Counts were performed in 10 fields of 1 mm2 and assigned
for necrosis severity using scores on a scale from 1–5: 1
(<5%), 2 (5–25%), 3 (25–50%), 4 (50–75%) and 5 (>75%)
[13].
Quantitative polymerase chain reaction (qPCR)
Intrarenal mRNA levels were analysed to determine the
expression of tumour necrosis factor (TNF)-a, interleukin
(IL)-6, IL-10, CCL2, C3 and CD86 in the experimental
groups. Samples were stored at -80°C in RNALater. Total
RNA was purified from 30 mg of tissue with an RNeasy kit
(Qiagen, Courtabouef, France). RNA integrity and quantity
were evaluated by spectrophotometry at 260 and 280 nm.
Complementary DNA (cDNA) was obtained with reverse
transcriptase using a First Strands Kit (SABiosciences,
Qiagen) from 0·7 mg of total isolated RNA. qPCR analyses
were performed with in an ABI Prism 7500 instrument and
a SYBR Green SuperScript kit (Qiagen). The glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene was used as a
control and its expression levels were used to normalize the
data. GAPDH levels were similar in all groups (data not
shown). To determine expression level, serial dilutions of
calibrator cDNA were made and a standard curve for each
gene was created. Ct values were compared to the cDNA
concentrations. The curve was used to determine the differ-
ences in the Ct value in each sample. The concentration of
each sample was calculated as a percentage of mRNA relative
to the calibrator, as per the DDCT (2-DD CT) method. Gene
expression results are reported as the variation or change
relative to the ventilated group; the expression value for each
gene was fixed at 1.
Renal myeloperoxidase
Renal myeloperoxidase (MPO) activity, which indicates
polymorphonuclear leucocyte (PMN) infiltration into the
kidney, was measured according to the protocol of Singbartl
et al. [14,15]. First, samples were homogenized in ice-cold
20 mM KPO4 buffer. After removing the supernatants by
centrifugation at 17 000 g, the pellets were resuspended
in ice-cold 20 mM KPO4 buffer followed by two more
centrifugations. Then, 0·5% (w/v) hexacyltrimethylammo-
nium bromide-10 mM ethylenediamine tetraacetic acid
(EDTA) in 50 mM KPO4 was added to the pellet. The sus-
pensions were sonicated, freeze-thawed and incubated for
20 min at 4°C. Supernatants (17 000 g) were used to measure
MPO with 3,3′-5,5′ tetramethylbenzidine (TMB) (1:5 v/v),
and the absorbance was recorded at 460 nm. Results are
expressed as units of MPO/mg supernatant protein as deter-
mined by the bicinchoninic acid assay (Pierce Chemical Co.,
Rockford, IL, USA).
Statistical analysis
Data are expressed as mean 6 standard deviation (s.d.). Dif-
ferences between groups or conditions were analysed by
analysis of variance (anova). When anova was significant,
multiple comparisons were performed with post-hoc
Student–Newman–Keuls test to locate the source of
difference. Non-parametric variables were analysed with the
Krustal–Wallis non-parametric test of anova. A P-value of
< 0·05 was considered statistically significant.
Results
Plasma urea and creatinine concentrations
Plasma levels of urea and creatinine were quantified
in all groups 2 h after the brain death diagnosis. Urea
levels in the groups were as follows: ventilated group
(V), 0·43 6 0·014 mg/dl and brain death group (BD),
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Fig. 1. Mean blood pressure evolution. Shown are changes in mean
blood pressure during brain death induction in rats. After brain death
was diagnosed, animals were ventilated for 2 h; during that time,
blood pressure was kept constant within 60–120 mmHg. In the cases
of hypotension, animals were treated with noradrenaline. Similar
levels were kept for the ventilated group (data not shown).
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groups was not statistically significant. Mean urea was
0·41 6 0·15 mg/dl in the rATG-treated group (BD and
rATG). The difference between this group and the BD
group was not significant. Mean creatinine levels were
0·88 6 0·22 mg/dl in the V group; 1·37 6 0·07 mg/dl in the
BD group (V versus BD: P < 0·01); and 0·64 6 0·02 mg/dl in
the BD and rATG group. The difference in plasma creatinine
between the BD and rATG group and the BD group was
significant (P < 0·001) (Fig. 2).
Necrosis and MPO
Kidney necrosis was evaluated with haematoxylin and
eosin staining of renal tissue. The BD group showed a sig-
nificantly higher ATN score than that in the V group at 2 h
after diagnosis (BD: 4·75 6 0·5 versus V: 2·25 6 0·5, P < 0·01;
Fig. 3a). The ATN score decreased to 2·75 6 0·5 in the
thymoglobulin-treated group, which was a significant
difference compared to that in the BD group (BD and rATG:
2·75 6 0·5 versus BD, 4·75 6 0·5, P < 0·01). Figure 3b shows
representative kidney tissue sections of each experimental
group. Renal MPO increased significantly after brain death
(V: 32 6 7·5 versus BD: 129 6 18, Fig. 3c) indicating
an almost fourfold increase in tissue PMN content. This
increase in MPO levels decreased significantly in the BD and
rATG group (BD: 129 6 18 versus BD and rATG: 110 6 14,
P < 0·05).
Quantification of inflammatory mediators
Expression levels of TNF-a, IL-6, IL-10, monocyte chemot-
actic protein 1 (CCL2), C3 and CD86 were evaluated in all
experimental groups using real-time PCR (Fig. 4 and Table 1
for RT–PCR primers). Inflammation was assessed through
expression of the proinflammatory genes TNF-a and IL-6.
In the BD group, TNF-a was 20 times higher than that in the
Fig. 2. Urea and creatinine scores. Two h after
brain death (BD) was diagnosed, blood samples
were collected and urea (a) and creatinine
(b) were evaluated. Data are expressed as
mean 6 standard deviation (s.d.), n = 5.
**P < 0·01 and ***P < 0·001 for comparison
with the BD group.
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Fig. 3. Acute tubular necrosis (ATN) quantifica-
tion. (a) ATN score in the three experimental
groups. Tables show mean 6 standard deviation
values (s.d.) of all animals in the three groups.
**P < 0·005 compared to the brain death group
(BD). (b) Haematoxylin and eosin (H&E)
staining, original magnification ¥20. Ventilated
(V) group: ATN 20% of parenchyma. Flattened
focal tubular epithelium and variable dilatation
observed. BD group: ATN 70% of parenchyma.
Denudation of epithelial membrane and haem-
orrhage focus. BD+rATG group: ATN 30% of
parenchyma. Expanded tubules with intralumi-
nal cell casts and loss of epithelial membrane or
replacement by squamous epithelium. (c) Renal
polymorphonuclear (PMN) infiltration was
analysed with myeloperoxidase (MPO) activity
determinations. Results are expressed as units
of MPO/mg of protein. Data are expressed
as mean 6 standard deviation (s.d.), n = 5.
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V group. Changes in TNF-a and IL-6 between the BD and
BD and rATG groups were not significant (P > 0·05).
However, animals in the BD and rATG group showed a sta-
tistically significant increase in IL-10 compared to that in the
BD group (P < 0·001).
We evaluated leucocyte migration and antigen presenter
cell activation through CCL2 and CD86 expression. CCL2
expression was 1·9 times higher in the BD group compared
to that in the V group. CCL2 expression decreased signifi-
cantly in the rATG group (P < 0·05). The difference in CD86
between the groups was not statistically significant. Comple-
ment C3 in the kidneys was evaluated as a determinant of
innate immune activation level, but the difference between
the groups was not significant.
Discussion
The significant pathophysiological alterations caused by
brain death in a potential organ to be transplanted result in
inflammation and injury, which eventually affect post-
transplant function and graft survival [16]. A comprehensive
understanding of this process is necessary to improve inter-
vention strategies. The results of our study suggest that rATG
administered to donors could improve kidneys affected by
brain death. Specifically, the treatment group showed a sig-
nificant decrease in ATN score and creatinine values, a sig-
nificant increase in IL-10 expression and a significantly lower
in-situ expression of CCL2.
The precise mechanism underlying the immunosuppres-
sive efficacy of rATG in renal transplant recipients is unclear,
although it has been attributed primarily to T cell depletion.
However, several other mechanisms may also be responsible.
Fig. 4. Determination of inflammatory
mediators. Intrarenal levels of mRNA for
tumour necrosis factor-alpha, interleukin
(IL)-6, IL-10, monocyte chemotactic protein 1
(MCP-1), C3 and CD86 in kidneys from brain
death group (BD) and treatment group
(BD+rATG). *P < 0·05 and ***P < 0·001
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IL: interleukin; MCP-1: monocyte chemotactic protein 1; TNF:
tumour necrosis factor.
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According to data mainly, but not exclusively, from pre-
clinical studies, rATG modulates the expression of several
lymphocyte surface antigens involved in a wide variety
of functions ranging from T cell activation to endothelial
adherence. rATG also activates certain transcription factors
and interferes with numerous immune cell processes such as
cytokine production, chemotaxis, endocytosis, stimulation
and proliferation [11,17,18].
Renal injury is generally assessed using functional markers
such as creatinine, and a histological damage marker such as
ATN. These markers decreased in our treatment group,
which may indicate that rATG administered after brain death
ameliorated renal damage caused by brain death. MPO, an
enzyme found in neutrophils and monocyte phagosomes, is
used as an indirect indicator of neutrophil infiltration. The
lower levels of MPO in the treatment group may have
occurred because rATG depletes neutrophils and interferes
with leucocyte–endothelium interactions through down-
regulation of integrin CD11a/CD18 (LFA-1) surface expres-
sion [17,18]. The depletion of neutrophils in kidney tissue
may be an indirect effect of rATG rather than a direct effect
of antibody depletion. It is possible that some antigens
detected by the antibody are common to thymocytes and
neutrophils. However, another explanation may be that cir-
culating T cells are depleted, and that these are responsible
for recruiting neutrophils.
During brain death, renal tissue is damaged through an
inflammatory process involving endothelial injury, leucocyte
infiltration and tubular epithelial cell damage [9]. During
this process, there appears to be increased in-situ and sys-
temic expression of proinflammatory cytokines, such as
TNF-a, IL-1, IL-6 and IL-8, leucocyte activation and
ICAM-1 and vascular adhesion molecule (VCAM-1) expres-
sion [19,20]. Surprisingly, we did not find any difference in
the in-situ expression of TNF-a, IL-6 or C3 between the
groups. This may be explained by the augmented expression
of TNF-a and IL-6 within the first 3 h after rATG adminis-
tration in addition to their increase as a result of brain death,
as shown by Guttman et al. [21].
Complement C3 gene expression may not be related to the
amount of C3 activated, which is relevant to kidney damage.
The importance of local renal complement C3 synthesis in
the pathogenesis of kidney damage after transplantation has
been described previously [16]. Donor kidneys from C3
knock-out mice show better survival rates after transplanta-
tion than kidneys from wild-type mice. Even though induc-
tion of renal complement C3 gene expression has been
credited to ischaemia/reperfusion injury during transplanta-
tion, the importance of donor C3 has been observed [22].
Induction of complement components in kidneys from
deceased donors occurs after cold ischaemia [23]. However,
our results did not demonstrate that donor local renal
complement expression in grafts from brain dead donors is
important for a good outcome after transplantation. More
studies are necessary to determine if local renal complement
expression and activation in brain dead donors might
actually be responsible for transplant outcome.
Although proinflammatory mediator expression between
the groups was not significantly different, decreased ATN in
the rATG group may be explained by significantly increased
in-situ over-expression of IL-10, which inhibits proinflam-
matory cytokines such as TNF-a. IL-10 is a pleiotropic, anti-
inflammatory cytokine with immunosuppressive properties
and the main inhibitory cytokine of TNF-a. Zeller et al. [24]
demonstrated that IL-10 and transforming growth factor
(TGF)-a have an additive effect as a tolerance inducer. IL-10
is associated with a diminished probability of interstitial
fibrosis and renal tubular atrophy when it is over-expressed
in situ in the renal parenchyma. Regulatory T cells seem to be
resistant to ATG-mediated T cell depletion and can even
suppress the recovery of T cells with an effector phenotype
[25]. However, Lopez et al. [25] showed that low, non-
depleting doses of rATG to peripheral blood mononuclear
cells could expand human CD4+CD25+forkhead box protein
3 (FoxP3+) regulatory T cells with suppressive properties in
vitro. The potential source of IL-10 was not investigated in
this study, but ATG can generate changes in different lym-
phocyte cell subsets in blood and regulatory T cells expan-
sion [26]. Liu et al. [27] showed that when CD4+ cells are
pretreated with ATG the regulatory T cells are expanded,
inducing IL-10 secretion. Of note, thymoglobulin has differ-
ent effects on each lymphocyte subset. We cannot verify this
finding, because immunophenotypic characterization of cell
infiltrates was not performed in our study. ATG-mediated
regulatory T cell expansion is a result of ATG-mediated
reprogramming of CD4+ and is dependent on signal trans-
ducer and activator of transcription-3 (STAT3). These modi-
fied CD4+ T cells induce IL-10 secretion only in the presence
of intact STAT3 signalling. IL-10 secretion subsequently pro-
motes CD14+ and CD11+ tolerogenic dentritic cells [28].
Another result worthy of note was the diminished expres-
sion of CCL2 in renal tissue of the treatment group. De Vries
et al. [9] demonstrated that CCL2 increases significantly in
grafts, attracting macrophages during brain death. CCL2, a
monocyte chemoattractant protein from the C-C chemokine
family, is associated with various diseases and inflamma-
tory processes [13]. It binds to its G-protein-coupled recep-
tor and triggers monocyte/macrophage migration and
infiltration. It also stimulates an inflammatory response that
increases IL-6 and interferon (IFN)-g [29]. Decreased CCL2
levels in the rATG-treated group may have caused lower
levels of monocyte/macrophage infiltration in renal tissue
and lower production of proinflammatory mediators, which
are responsible for ATN of renal tubular epithelial cells. It is
not yet clear how ATG diminishes CCL2, but a possible
explanation may be the presence of anti-CCL2 antibodies in
rATG.
rATG is administered typically to renal transplant recipi-
ents, and it has begun to play a role in preventing ischaemia/
reperfusion injury. Aiello et al. [11] demonstrated that rATG
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is effective in preventing impaired renal function and tissue
damage when the drug is administered to recipients at
22 mg/kg beginning 2 h before transplantation.
This is the first experimental study to administer ATG to
potential donors during brain death. Our results suggest that
ATG administered during brain death may ameliorate renal
injury before cold ischaemia. The main limitation of this
study is the observation time of 2 h; therefore, it would be
beneficial to design future experimental models with longer
observation times. Additionally, while the RT–PCR data
showed changes in gene expression, these changes are not
always related directly to protein expression. Some cytokines
can be controlled post-translationally; therefore, mRNA
levels may not be proportional to protein levels. Further
research should include transplantation in a model and
rATG administration to donors and recipients to compare
effects. In conclusion, considering that research on donor
management and organ preservation offers realistic hopes to
improve transplantation outcomes [4], our findings could
contribute in the search for specific cytoprotective interven-
tions to improve the quality and viability of transplanted
organs.
Acknowledgements
This work was financed by Foundation for Research and
Assistance in Kidney Disease (FINAER), Buenos Aires and
Genzyme de Argentina S.A.
Disclosure
The authors declare no conflicting interests.
References
1 Nijboer WN, Ottens PJ, van Dijk A, van Goor H, Ploeg RJ, Leu-
venink HG. Donor pretreatment with carbamylated erythropoietin
in a brain death model reduces inflammation more effectively than
erythropoietin while preserving renal function. Crit Care Med
2010; 38:1155–61.
2 Diethelm AG, Blackstone EH, Naftel DC et al. Important risk
factors of allograft survival in cadaveric renal transplantation.
A study of 426 patients. Ann Surg 1988; 207:538–48.
3 Schuurs TA, Gerbens F, van der Hoeven JA et al. Distinct transcrip-
tional changes in donor kidneys upon brain death induction in
rats: insights in the processes of brain death. Am J Transplant 2004;
4:1972–81.
4 Feng S. Donor intervention and organ preservation: where is
the science and what are the obstacles? Am J Transplant 2010;
10:1155–62.
5 Demetrios J, Kutsogiannis G, Pagliarello G et al. Medical manage-
ment to optimize donor organ potential: review of the literature.
Can J Anesth 2006; 53:820–30.
6 Morariu AM, Schuurs TA, Leuvenink HG et al. Early events in
kidney donation: progression of endothelial activation, oxidative
stress and tubular injury after brain death. Am J Transplant 2008;
8:933–41.
7 Pratschke J, Kofla G, Wilhelm MJ et al. Improvements in early
behavior of rat kidney allografts after treatment of the brain dead
donor. Ann Surg 2001; 234:732–40.
8 Pratschke J, Wilhelm MJ, Kusaka M et al. Accelerated rejection of
renal allografts from brain dead donors. Ann Surg 2000; 232:263–
71.
9 De Vries DK, Lindeman JHN, Ringers J, Reinder MEJ, Rabelink TJ,
Schaapherder AFM. Donor brain death predisposes human kidney
grafts to a proinflammatory reaction after transplantation. Am J
Transplant 2011; 11:1064–70.
10 Kuecuek O, Mantouvalou L, Klemz R et al. Significant reduction of
proinflammatory cytokines by treatment of the brain-dead donor.
Transplant Proc 2005; 37:387–8.
11 Aiello S, Cassis P, Mister M et al. Rabbit anti-rat thymocyte immu-
noglobulin preserves renal function during ischemia/reperfusion
injury in rat kidney. Transpl Int 2011; 24:829–38.
12 Zhou H, Liu J, Pan P, Jin D, Ding W, Li W. Carbon monoxide
inhalation decreased lung injury via anti-inflammatory and anti-
apoptotic effects in brain death rats. Exp Biol Med (Maywood)
2010; 235:1236–43.
13 Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C. The role
of monocyte chemoattractant protein MCP1/CCL2 in neuroin-
flammatory diseases. J Neuroimmunol 2010; 224:93–100.
14 Singbartl K, Ley K. Protection from ischemia–reperfusion induced
severe acute renal failure by blocking E-selectin. Crit Care Med
2000; 28:2507–14.
15 Singbartl K, Green SA, Ley K. Blocking P-selectin protects from
ischemia/reperfusion-induced acute renal failure. FASEB J 2000;
14:48–54.
16 Damman J, Hoeger S, Boneschansker L et al. Targeting comple-
ment activation in brain-dead donors improves renal function after
transplantation. Transplant Immunol 2011; 24:233–7.
17 Beiras-Fernandez A, Walther S, Thein E, Muenzing S,
Hammer C. Influence of polyclonal ATGs on expression of adhe-
sion molecules: an experimental study. Transplant Proc 2005;
37:1944–6.
18 Preville X, Flacher M, LeMauff B et al. Mechanisms involved in
antithymocyte globulin immunosuppressive activity in a nonhu-
man primate model. Transplantation 2001; 71:460–8.
19 Donnahoo KK, Shames BD, Harken AH, Meldrum DR. Review
article: the role of tumor necrosis factor in renal ischemia–
reperfusion injury. J Urol 1999; 162:196–203.
20 Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3
is a determinant of postischemic acute renal failure. FASEB J 2006;
20:217–26.
21 Guttman RD, Caudrelier P. Pharmacokinetics, foreign protein
immune response, cytokine release and lymphocyte subsets in
patients receiving thymoglobuline and immunosuppression.
Transplant Proc 1997; 29:24–6S.
22 Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement
component C3 regulates acute renal transplant rejection. Nat Med
2002; 8:582–7.
23 Naesens M, Li L, Ying L et al. Expression of complement compo-
nents differs between kidney allografts from living and deceased
donors. J Am Soc Nephrol 2009; 20:1839–51.
24 Zeller JC, Panoskaltsis-Mortari A, Murphy WJ et al. Induction of
CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and
TGF-beta. J Immunol 1999; 163:3684–91.
25 Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel
mechanism of action for anti-thymocyte globulin: induction of
F. Cicora et al.
336 © 2012 The Authors
Clinical and Experimental Immunology © 2012 British Society for Immunology, Clinical and Experimental Immunology, 169: 330–337
CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006;
17:2844–53.
26 De Serres SA, Yeung MY, Mfarrej BG, Najafian N. Effect of biologic
agents on regulatory T cells. Transplant Rev (Orlando) 2011;
25:110–16.
27 Liu Z, Fang Y, Wang X et al. Upregulation of molecules associated
with T-regulatory function by thymoglobulin pretreatment of
human CD4+ cells. Transplantation 2008; 86:1419–26.
28 Boenisch O, Lopez M, Elyaman W, Magee CN, Ahmad U, Najafian
N. Ex vivo expansion of human Tregs by rabbit ATG is dependent
on intact STAT3-signaling in CD4+ T cells and requires the pres-
ence of monocytes. Am J Transplant 2012; 12:856–66; doi: 10.1111/
j.1600-6143.2011.03978.x.
29 Kolattukudy PE, Quach T, Bergese S et al. Myocarditis induced by
targeted expression of the MCP-1 gene in murine cardiac muscle.
Am J Pathol 1998; 152:101–11.
Renal damage amelioration by rATG to donors
337© 2012 The Authors
Clinical and Experimental Immunology © 2012 British Society for Immunology, Clinical and Experimental Immunology, 169: 330–337
